Benefits
Appetite suppression via serotonin elevation
HCA inhibits ATP-citrate lyase, causing acetyl-CoA to accumulate and potentially increase malonyl-CoA — which signals hypothalamic satiety centers. HCA may also increase serotonin availability by reducing its catabolism, producing mild appetite-suppressing effects. Some studies show reduced food intake with HCA supplementation, though effects are not consistent across all trials.
Modest fat synthesis inhibition
ATP-citrate lyase (ACLY) catalyzes the conversion of citrate to acetyl-CoA in the cytosol — the first committed step in de novo lipogenesis (fat synthesis from carbohydrates). HCA competitively inhibits ACLY, theoretically reducing the conversion of dietary carbohydrates to fat. Laboratory evidence for this mechanism is strong; human clinical significance is debated.
Glycogen synthesis promotion
By inhibiting ACLY and redirecting acetyl-CoA away from fat synthesis, HCA may promote glycogen synthesis in liver and muscle — improving carbohydrate storage rather than fat storage. Some studies show improved exercise endurance and glycogen preservation with HCA, though evidence is limited.
Mechanism of action
ATP-citrate lyase competitive inhibition
HCA competitively inhibits ATP-citrate lyase (ACLY) by mimicking the transition state of the enzyme-substrate complex. ACLY normally converts mitochondria-exported citrate to acetyl-CoA and oxaloacetate in the cytosol — the rate-limiting step providing acetyl-CoA for fatty acid synthesis and cholesterol synthesis. HCA inhibition reduces cytosolic acetyl-CoA availability for these anabolic pathways.
Serotonin and appetite signaling modulation
Elevated malonyl-CoA from ACLY inhibition activates hypothalamic AMPK, which may modulate serotonin turnover and appetite signaling. Animal studies show increased brain serotonin with HCA — contributing to appetite suppression and reduced food intake, though human evidence for this specific pathway is weak.
Cortisol reduction and stress eating modulation
HCA has demonstrated cortisol-lowering effects in some clinical studies, which may reduce stress-induced eating. The proposed mechanism involves adrenal steroidogenesis modulation, though this pathway is not well-characterized in humans.
Clinical trials
Evidence review and pooled analysis of randomized controlled trials examining HCA/Garcinia cambogia for weight loss. (J Obes — or 2018 update)
Pooled across HCA clinical trials.
HCA produced statistically significant but clinically modest weight loss (~0.88 kg additional vs placebo over 8-12 weeks). Effect size very small — Garcinia is not a meaningful weight loss intervention. Critical hepatotoxicity concern: multiple case reports and case series have linked Garcinia cambogia products to acute hepatotoxicity, sometimes severe (acute liver failure, transplant). The 2017 Hydroxycut hepatotoxicity issues, while multi-ingredient, included Garcinia. NIH LiverTox database lists Garcinia as a documented cause of drug-induced liver injury. The widespread weight loss marketing greatly exceeds the modest evidence and substantial safety concerns.